Artificial Intelligence healthcare company Tempus AI is set to release its fiscal 2025 Q2 earnings report before the U.S. market opens on August 8.

According to Bloomberg's consensus forecast, Tempus AI is expected to report $297 million in revenue, reflecting a 79% year-on-year increase. Adjusted net profit is projected at -$43 million, and adjusted EPS is expected to be -$0.24.

Q1 Review

In the fiscal 2025 first quarter, Tempus AI delivered a robust earnings report, exceeding market expectations in revenue and business growth. The company achieved revenue of $255.7 million, up by 75.4% year-on-year, primarily driven by its genomics business. The oncology testing segment and genetic testing from Ambry Genetics contributed significantly to this growth.

Although its GAAP net loss widened to $68.04 million, adjusted EBITDA losses narrowed to $16.2 million, demonstrating steady improvement in profitability. Data and service revenue also performed well, reaching $61.9 million, representing a 43.2% year-on-year increase.

Additionally, during Q1, the company signed a $200 million data licensing agreement with AstraZeneca and Pathos, pushing its total contract value past $1 billion by the end of the quarter. Based on this progress, Tempus raised its full-year revenue guidance to $1.25 billion and projected positive adjusted EBITDA, signaling a potential profitability turning point.

Q2 Key Highlights

Core Business Drivers

The genomics business continues to be the primary revenue driver for Tempus AI. In Q1, this segment generated $193.8 million in revenue, marking an 89% year-on-year growth. The market will focus on clinical progress for its newly launched xH whole-genome sequencing product and regulatory advancements for XT testing toward FDA approval, which could further boost average selling prices. Meanwhile, Ambry Genetics’ Q1 revenue increased by 23%, surpassing market expectations. If this trend persists, it could provide additional support for the company's annual performance.

The data and services segment also experienced rapid growth, with Q1 revenue reaching $61.9 million, a 43% year-on-year increase. Insights data licensing grew by 58%. For the current quarter, attention will be on progress in multimodal model development with AstraZeneca and Pathos (the first model is expected to launch within 9–12 months) as well as execution pace of the company’s $1 billion backlog in outstanding contract value.

Additionally, the acquisition of Deep 6 AI has enhanced Tempus’ data connectivity capabilities, potentially expanding its ecosystem influence among clinical and research institutions.

Strategic Initiatives and Product Development

The company is deepening collaborations and driving product innovations. Its three-year partnership with AstraZeneca is anticipated to yield $200 million in revenue, setting a template for similar future joint ventures. Moreover, its AI-powered health assistant for patients, Olivia, is helping Tempus expand beyond B2B applications into B2C scenarios, integrating electronic health records from over 1,000 health systems to boost user engagement and data-loop capabilities.

Market Focus

Profitability improvement remains a key concern for investors. Although Tempus has raised its annual revenue guidance to $1.25 billion (up 80% year-on-year) and expects positive adjusted EBITDA of $5 million, it still falls short of achieving full profitability. Investors will closely monitor whether Q2 results show continued reduction in losses as a key indicator of successful transformation.

On the valuation front, Tempus has a forward price-to-sales ratio of 7.5x, higher than the industry average of 5.8x. Clear signs of profitability improvement are needed to justify continued premium valuation. Some analysts have set a target price of $66, assuming stable business growth momentum.

Analysts' Perspectives

Most institutions have expressed optimism for Tempus' long-term outlook, citing the synergy between genomics and data businesses, the first-mover advantage of its AI platform, and deep collaborations with major pharmaceutical companies, which collectively build a strong commercial moat. However, some voices have cautioned that the current valuation already reflects much of the growth expectations, and if the earnings report fails to show accelerated profitability signals, the stock may face temporary pressure.

Summary

Tempus AI is expected to show continued strong revenue growth in its fiscal 2025 second-quarter earnings report. Market attention will focus on gross margin improvement, execution progress for major collaboration projects, and potential updates to its full-year guidance. While the company has established a leading position in AI-driven medical diagnostics, investors must balance short-term financial pressures against its long-term growth potential given the high valuation.

This earnings call will be pivotal, with management likely addressing the following key topics:

• Phase advancements and timeline for the AstraZeneca collaboration

• Growth sustainability post-integration of Ambry Genetics

• Visibility into profitability improvement

• Commercialization progress of new products like the xH sequencing and Olivia health assistant

Overall, Tempus AI is poised to deliver an impressive revenue report, but market focus will remain on its pathway toward profitability and whether strategic initiatives can effectively support future growth. For long-term investors optimistic about the AI healthcare space, this earnings report will serve as a crucial checkpoint in assessing Tempus' transition from "high growth" to "high-quality growth."

This content is based on Tiger AI and Bloomberg data and is intended for reference only.